Daiying Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daiying Zhang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Jie Cheng
School of Nursing, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China
2 shared publications- Xiaoxia Duan
Department of Anesthesiology, The Affiliated Hospital, Southwest Medical University, Luzhou, China
2 shared publications - Ana Kowark
Department of Anaesthesiology and Intensive Care Medicine University Hospital Bonn Bonn Germany
1 shared publication Fuli Huang
Department of Infectious Diseases, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China
1 shared publicationHongxia Zhang
School of Nursing, Southwest Medical University, 646000 Luzhou, Sichuan, China
1 shared publication- Jian Tang
Department of Infectious Diseases, The Affiliated Hospital, Southwest Medical University, Luzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 5351-5364
What are the Real-Life Dilemmas and Facilitators of Medication Adherence of Patients with Drug-Resistant Tuberculosis: A Qualitative Exploration of Patient Perspectives
Introduction: Drug-resistant tuberculosis (DR-TB) constitutes a global public health crisis, which endangers patients’ health, poses a significant transmission risk, and imposes a substantial strain on the healthcare system. Medication adherence is essential for enhancing treatment outcomes and mitigating the proliferation of DR-TB. Purpose: This study aims to explore the real-life dilemmas and facilitators affecting medication adherence in DR-TB patients and provide a reference for improving medication compliance in DR-TB patients. Patients and Methods: A descriptive qualitative study was conducted. 26 patients with DR-TB who were treated with oral medication regimen in a tertiary hospital in Luzhou City, Sichuan Province from March to May 2025 were selected through purposive sampling method for semi-structured interviews, and thematic analysis was used to analyze the data. Results: Five themes and fourteen sub-themes affecting medication adherence of DR-TB patients were identified, encompassing: Individual physiological traits (age-related variations in the perception of future time, polypharmacy in patients with comorbidities), intricate psychology and behaviors (misconceptions of medication effects, psychological distress resulting from stigma, misunderstanding of disease conditions, downward social comparison, divergences in medicine administration practices), synergy in social networks (multi-dimensional support of family members, support and communication from health providers), differences in family finances and living situations (significant family financial strain, influence of family roles), and constraints on medical insurance services (disparities in health insurance coverage, intricacy of the reimbursement procedure, constraints on reimbursement amounts and coverage). Conclusion: Adherence to medication among DR-TB patients is influenced by intricate factors. Health professionals should intervene on the basis of a comprehensive and dynamic assessment of medication adherence to address these influencing factors at various levels, thereby enhancing adherence and therapeutic outcomes.
- 1 October 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 5351-5364
Open AccessWhat are the Real-Life Dilemmas and Facilitators of Medication Adherence of Patients with Drug-Resistant Tuberculosis: A Qualitative Exploration of Patient Perspectives
Introduction: Drug-resistant tuberculosis (DR-TB) constitutes a global public health crisis, which endangers patients’ health, poses a significant transmission risk, and imposes a substantial strain on the healthcare system. Medication adherence is essential for enhancing treatment outcomes and mitigating the proliferation of DR-TB. Purpose: This study aims to explore the real-life dilemmas and facilitators affecting medication adherence in DR-TB patients and provide a reference for improving medication compliance in DR-TB patients. Patients and Methods: A descriptive qualitative study was conducted. 26 patients with DR-TB who were treated with oral medication regimen in a tertiary hospital in Luzhou City, Sichuan Province from March to May 2025 were selected through purposive sampling method for semi-structured interviews, and thematic analysis was used to analyze the data. Results: Five themes and fourteen sub-themes affecting medication adherence of DR-TB patients were identified, encompassing: Individual physiological traits (age-related variations in the perception of future time, polypharmacy in patients with comorbidities), intricate psychology and behaviors (misconceptions of medication effects, psychological distress resulting from stigma, misunderstanding of disease conditions, downward social comparison, divergences in medicine administration practices), synergy in social networks (multi-dimensional support of family members, support and communication from health providers), differences in family finances and living situations (significant family financial strain, influence of family roles), and constraints on medical insurance services (disparities in health insurance coverage, intricacy of the reimbursement procedure, constraints on reimbursement amounts and coverage). Conclusion: Adherence to medication among DR-TB patients is influenced by intricate factors. Health professionals should intervene on the basis of a comprehensive and dynamic assessment of medication adherence to address these influencing factors at various levels, thereby enhancing adherence and therapeutic outcomes.
- Open Access
- 4 February 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (4) , 2903-2913
Effect of parecoxib on postoperative delirium in patients with hyperlipidemia: a randomized, double-blind, single-center, superiority trial
Background: Hyperlipidemia has been implicated in the higher risk of developing postoperative delirium. Prostaglandin endoperoxide synthase-2 mediates neuroinflammatory processes in postoperative delirium. This study aims to investigate whether preoperative administration of parecoxib is more efficient than a placebo in averting postoperative delirium in patients with hyperlipidemia. Materials and methods: In this randomized, double-blind, superiority trial, participants with hyperlipidemia were randomized in a 1:1 ratio to receive parecoxib (40 mg parecoxib administered intravenously before anesthesia induction) or placebo (normal saline). The primary outcome was postoperative delirium incidence within three days, with a 5.4% difference set as the superiority threshold. Secondary outcomes were cumulative incidences of emergence delirium and prostaglandin endoperoxide synthase-2 levels, inflammatory cell counts, and pain score on postoperative day 1 and postoperative adverse events. Results: This trial conducted between August 2023 and August 2024 at a tertiary hospital in China included 452 adults with hyperlipidemia, with 226 in the parecoxib group and 226 in the placebo group. The incidence of postoperative delirium in the parecoxib group was 13.72%, a reduction of 12.39% compared to the placebo group (hazard ratio, 0.491; 95% confidence interval: 0.318 to 0.759; P < 0.001). The parecoxib group also had a lower incidence of emergence delirium, prostaglandin endoperoxide synthase-2 levels, white blood cell counts and neutrophil, and pain scores on postoperative day 1. The occurrence of adverse events was comparable between the two groups. Prostaglandin endoperoxide synthase-2 expression levels, white blood cell counts, and pain scores mediated the reduction of postoperative delirium incidence by parecoxib. Conclusion: Parecoxib may help in reducing the hyperlipidemia-related postoperative delirium incidence. The effective anti-inflammatory activity of prostaglandin endoperoxide synthase-2 inhibition by parecoxib and postoperative pain control may be important mechanisms for preventing postoperative delirium.
- 4 February 2025
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (4) , 2903-2913
Open AccessEffect of parecoxib on postoperative delirium in patients with hyperlipidemia: a randomized, double-blind, single-center, superiority trial
Background: Hyperlipidemia has been implicated in the higher risk of developing postoperative delirium. Prostaglandin endoperoxide synthase-2 mediates neuroinflammatory processes in postoperative delirium. This study aims to investigate whether preoperative administration of parecoxib is more efficient than a placebo in averting postoperative delirium in patients with hyperlipidemia. Materials and methods: In this randomized, double-blind, superiority trial, participants with hyperlipidemia were randomized in a 1:1 ratio to receive parecoxib (40 mg parecoxib administered intravenously before anesthesia induction) or placebo (normal saline). The primary outcome was postoperative delirium incidence within three days, with a 5.4% difference set as the superiority threshold. Secondary outcomes were cumulative incidences of emergence delirium and prostaglandin endoperoxide synthase-2 levels, inflammatory cell counts, and pain score on postoperative day 1 and postoperative adverse events. Results: This trial conducted between August 2023 and August 2024 at a tertiary hospital in China included 452 adults with hyperlipidemia, with 226 in the parecoxib group and 226 in the placebo group. The incidence of postoperative delirium in the parecoxib group was 13.72%, a reduction of 12.39% compared to the placebo group (hazard ratio, 0.491; 95% confidence interval: 0.318 to 0.759; P < 0.001). The parecoxib group also had a lower incidence of emergence delirium, prostaglandin endoperoxide synthase-2 levels, white blood cell counts and neutrophil, and pain scores on postoperative day 1. The occurrence of adverse events was comparable between the two groups. Prostaglandin endoperoxide synthase-2 expression levels, white blood cell counts, and pain scores mediated the reduction of postoperative delirium incidence by parecoxib. Conclusion: Parecoxib may help in reducing the hyperlipidemia-related postoperative delirium incidence. The effective anti-inflammatory activity of prostaglandin endoperoxide synthase-2 inhibition by parecoxib and postoperative pain control may be important mechanisms for preventing postoperative delirium.
- Open Access
- 19 February 2024
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 23 (2) , 40
Association between Dyslipidaemia and Cognitive Impairment: A Meta-Analysis of Cohort and Case-Control Studies
Background: This study explored the specific relationship between different lipid indicators and cognitive impairment and aimed to provide a reference for implementing targeted lipid regulation measures to prevent and alleviate cognitive impairment. Methods: We searched three databases (PubMed, Embase, and Web of Science) for literature related to hyperlipidaemia, lipid levels, and cognitive impairment, and used the Newcastle-Ottawa Scale to evaluate the quality of the identified literature. A meta-analysis was performed using RevMan 5.4, and the combined effect size ratio using a random-effects model (odds ratio [OR] and 95% confidence interval [CI]) was used to evaluate the association between dyslipidaemia and cognitive impairment. Results: Among initially identified 2247 papers, we ultimately included 18 studies involving a total of 758,074 patients. The results of the meta-analysis revealed that patients with hyperlipidaemia had a 1.23-fold higher risk of cognitive impairment than those with normal lipid levels (OR = 1.23, 95% CI: 1.04–1.47, p = 0.02). Further subgroup analysis showed that elevated total cholesterol (TC) levels increased the risk of cognitive impairment by 1.59-fold (OR = 1.59, 95% CI: 1.27–2.01, p < 0.0001) and were more significant in older or male patients. Moreover, elevated triglyceride levels were inversely correlated with cognitive disorders, whereas elevated low-density lipoprotein cholesterol levels were unrelated to cognitive impairment risk. Conclusions: Dyslipidaemia was strongly associated with cognitive impairment, and elevated TC levels were a risk factor for cognitive impairment. Furthermore, the damaging effects of elevated TC levels on cognition were more pronounced in older and male populations.
- 19 February 2024
- Published by IMR Press in Journal of Integrative Neuroscience
- Vol. 23 (2) , 40
Open AccessAssociation between Dyslipidaemia and Cognitive Impairment: A Meta-Analysis of Cohort and Case-Control Studies
Background: This study explored the specific relationship between different lipid indicators and cognitive impairment and aimed to provide a reference for implementing targeted lipid regulation measures to prevent and alleviate cognitive impairment. Methods: We searched three databases (PubMed, Embase, and Web of Science) for literature related to hyperlipidaemia, lipid levels, and cognitive impairment, and used the Newcastle-Ottawa Scale to evaluate the quality of the identified literature. A meta-analysis was performed using RevMan 5.4, and the combined effect size ratio using a random-effects model (odds ratio [OR] and 95% confidence interval [CI]) was used to evaluate the association between dyslipidaemia and cognitive impairment. Results: Among initially identified 2247 papers, we ultimately included 18 studies involving a total of 758,074 patients. The results of the meta-analysis revealed that patients with hyperlipidaemia had a 1.23-fold higher risk of cognitive impairment than those with normal lipid levels (OR = 1.23, 95% CI: 1.04–1.47, p = 0.02). Further subgroup analysis showed that elevated total cholesterol (TC) levels increased the risk of cognitive impairment by 1.59-fold (OR = 1.59, 95% CI: 1.27–2.01, p < 0.0001) and were more significant in older or male patients. Moreover, elevated triglyceride levels were inversely correlated with cognitive disorders, whereas elevated low-density lipoprotein cholesterol levels were unrelated to cognitive impairment risk. Conclusions: Dyslipidaemia was strongly associated with cognitive impairment, and elevated TC levels were a risk factor for cognitive impairment. Furthermore, the damaging effects of elevated TC levels on cognition were more pronounced in older and male populations.